Journal of Clinical Investigation· 2026Q1
Interferon-λ inhibits immunopathology and boosts T cell–mediated immunity in a mouse model of mucosal viral infection
- 1citations
- Q1SCImago
- 2026year
Short summary
Mucosal delivery of Interferon-lambda (IFN-λ) abrogates HSV-2-induced vaginal tissue pathology by inhibiting IL-6 production and rescues local IFN-γ production, boosting CD4+ T cell responses.
AI-generated from the title and abstract; the full text is not read.
Key points
- Mucosal IFN-λ delivery prevents HSV-2-induced vaginal tissue pathology in mice.
- IFN-λ inhibits IL-6 production, a key driver of pathology.
- IFN-λ rescues CD4+ T cell-dependent IFN-γ production, essential for protection.
- IFN-λ enhances monocyte-derived antigen-presenting cell differentiation, boosting T cell responses.
AI-generated from the title and abstract; the full text is not read.
Abstract
Interferon lambda (IFN-λ) has emerged as a critical inducer of immune regulation in addition to its mucosal antiviral properties. However, the cellular and molecular mechanisms that govern its dual role during viral infections remain unclear. Here, we discovered that mucosal delivery of IFN-λ abrogates the herpes simplex virus type 2–induced (HSV-2-induced) vaginal tissue pathology observed in the absence of type I IFN signaling, through drastically inhibiting IL-6 production. At the same time, we demonstrated that IFN-λ rescued local production of CD4 + T cell–dependent IFN-γ, which is essential for protection against the development of toxic megacolon following genital HSV-2 infection. Mechanistically, we found that IFN-λ enhances the differentiation of CCR2 + Ly6C hi cells into monocyte-derived antigen-presenting cells, thereby boosting T cell responses. In vivo depletion of CCR2 + cells abrogated this phenomenon. Together, these findings suggest that IFN-λ orchestrates a potent antiviral response, inhibiting hyperinflammatory responses while selectively augmenting effector T cell function. This study positions IFN-λ as a promising therapeutic candidate for enhancing local antiviral immunity and offers new insights into the regulation of immune responses in the context of mucosal viral infections.
The authors' abstract, as published at the source. Journal of Clinical Investigation, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
ImmunologyImmunology and Microbiology